Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti‐epidermal growth factor receptor monoclonal antibodies: A meta‐analysis. Issue 8 (4th July 2013)

• Record Type: Journal Article
• Authors: Xu, Qi; Xu, An Tao; Zhu, Ming Ming; Tong, Jin Lu; Xu, Xi Tao; Ran, Zhi Hua
• Is Part Of: Journal of digestive diseases. Volume 14:Issue 8(2013:Aug.)
• Page Start: 409
• Page End: 416
• Publication Date: 2013-07-04
• Subjects: Digestive organs -- Diseases -- Periodicals; Gastroenterology -- Periodicals; 616.3
• DOI: 10.1111/1751-2980.12063
• Languages: English
• ISSNs: 1751-2972

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="cdd12063-sec-0001" sec-type="section"> <title>Objective</title> <p>This study aimed to evaluate the predictive and prognostic roles of <italic>BRAF</italic> mutation in patients with metastatic colorectal cancer (mCRC) treated with anti‐epidermal growth factor receptor (EGFR) monoclonal antibodies (MoAbs).</p> </sec> <sec id="cdd12063-sec-0002" sec-type="section"> <title>Methods</title> <p>Computer searches of the literature on <italic>BRAF</italic> mutation in mCRC patients were performed. Studies with objective response rate (ORR) to anti‐EGFR MoAbs and/or overall survival (OS) and progression‐free survival (PFS) with different <italic>BRAF</italic> gene expression in mCRC patients were eligible.</p> </sec> <sec id="cdd12063-sec-0003" sec-type="section"> <title>Results</title> <p>A total of 19 studies including 2875 patients was enrolled in the meta‐analysis. <italic>BRAF</italic> mutation was detected in 246 patients. The ORR was 18.4% (40/217) in mutant <italic>BRAF</italic> group and 41.7% (831/1993) in the wild‐type <italic>BRAF</italic> group. The overall risk ratio (RR) for the ORR of <italic>BRAF</italic> mutation patients compared with wild‐type <italic>BRAF</italic> patients was 0.58 (95% confidence intervals [CI] 0.35–0.94, <italic>P</italic> = 0.027). The median PFS of patients with <italic>BRAF</italic> mutation was significantly shorter than that of patients with wild‐type <italic>BRAF</italic> (hazard ratio [HR] 2.98, 95% CI 2.07–4.27, <italic>P</italic> < 0.001) and the median OS of patients with <italic>BRAF</italic> mutation was also significantly shorter than that of those with wild‐type <italic>BRAF</italic> (HR 2.85, 95% CI 2.31–3.52, <italic>P</italic> < 0.001).</p> </sec> <sec id="cdd12063-sec-0004" sec-type="section"> <title>Conclusion</title> <p> <italic>BRAF</italic> mutation is associated with poor response to anti‐EGFR MoAbs and it is an adverse prognostic biomarker of the survival of patients with mCRC.</p> </sec> </abstract>